Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

Launched by WUHAN UNION HOSPITAL, CHINA · Jul 1, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how artificial intelligence (AI) and special imaging techniques can help predict how patients with liver cancer (specifically hepatocellular carcinoma) will respond to immunotherapy, a type of treatment that helps the immune system fight cancer. By analyzing CT and MRI scans taken before—and possibly after—treatment, the researchers hope to better understand which patients are more likely to benefit from immunotherapy and how long they might survive.

To join this study, patients must have been treated for liver cancer at Wuhan Union Hospital between July 2025 and July 2026, be over 18 years old, and have at least one CT or MRI scan taken before starting treatment. Their cancer diagnosis must also be confirmed through a tissue biopsy, which is a small sample of the tumor examined under a microscope. Participants will have their imaging data reviewed using computer programs that automatically identify the tumor and extract important features to build a prediction model. This study is currently recruiting patients of all genders aged 65 to 74. If you or a loved one fits these criteria, this trial could help improve how doctors choose and monitor treatments for liver cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients were treated for hepatocellular carcinoma in Wuhan Union Hospital from July 2025 to July 2026;
• • 2. Aged \> 18 years old;
• • 3. At least one CT scan or MR scan before treatment;
• • 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors.
• Exclusion criteria:
• • 1. Poor image quality;
• • 2. Incomplete clinical data or loss of follow-up;
• • 3. Presence of another primary malignancy other than liver cancer;
• • 4. Unclear pathological diagnosis.